Form 4: Teva Exec Sells Shares

Teva Pharmaceutical Industries Ltd. executive Mark Sabag reported the sale of 80,760 ordinary shares.

Summary

• Mark Sabag, Executive Vice President of International Markets Commercial at Teva Pharmaceutical Industries Ltd., sold 80,760 ordinary shares.
• The transactions occurred on May 1, 2026, with shares sold at a weighted average price of $34.9918.
• The sale prices ranged from $34.935 to $35.07 per share.
• Following the sale, Sabag beneficially owns 144,180 ordinary shares directly.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing as having a slightly negative sentiment due to the sale of a significant number of shares by an executive, which can sometimes signal a lack of confidence or a need for personal liquidity.

Negatives

• Executive Mark Sabag sold a significant number of shares (80,760).

Future Outlook

No forward-looking statements or guidance were provided in this filing.

Industry Context

StockSavvy.ai notes that Form 4 filings typically report transactions by company insiders, such as executives and directors. These filings are closely watched by investors for insights into insider confidence and potential stock price movements.

Stakeholder Impact

• Shareholders may view the sale of shares by an executive with concern, potentially impacting investor sentiment.
• The sale does not directly impact employees, customers, suppliers, or creditors based on the information provided.

Key Dates

Recommendation

The filing reports an insider sale, which warrants attention. However, without further context on the executive's overall holdings, reasons for the sale, or the company's broader financial performance, a 'hold' recommendation is prudent. Investors should monitor future filings and company announcements for additional insights.

Keywords

Teva Pharmaceutical Industries, Form 4, Insider Trading, Share Sale, Mark Sabag, Executive Sale